ALS Research Collaborative
Launched by ALS THERAPY DEVELOPMENT INSTITUTE · Mar 13, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The ALS Research Collaborative is a study aimed at understanding more about amyotrophic lateral sclerosis (ALS) and related conditions. Researchers want to gather information about how these diseases affect people, which can help in developing new treatments and finding better ways to measure how effective they are. This study is open to adults aged 18 and older who either have a diagnosis of ALS or another motor neuron disease, or who carry a known gene mutation linked to ALS. Healthy volunteers can also participate.
If you decide to join the study, you can provide information about your health and experiences either online or through other remote methods. The study is currently looking for participants, and it's important to note that you should be able to communicate in written English and not have significant cognitive impairment that would affect your ability to understand the study. Your participation could help advance research that may benefit many people living with ALS in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years of age or older
- • Can communicate in written English
- • Has a diagnosis of ALS/MND or is a known carrier of an ALS associated mutation
- Exclusion Criteria:
- • Significant cognitive impairment that would prevent individual completion and understanding of the informed consent process.
About Als Therapy Development Institute
The ALS Therapy Development Institute (ALS TDI) is a leading nonprofit biotechnology organization dedicated to accelerating the development of effective treatments for amyotrophic lateral sclerosis (ALS). Founded by a team of scientists and advocates, ALS TDI focuses on rigorous preclinical research and innovative drug discovery methodologies to identify and advance promising therapeutic candidates. With a commitment to collaboration and transparency, the institute works closely with academic institutions, pharmaceutical companies, and the ALS community to foster groundbreaking research and ultimately improve the lives of those affected by this devastating disease. Through its comprehensive approach, ALS TDI strives to bring hope and tangible solutions to patients and families impacted by ALS.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Watertown, Massachusetts, United States
Patients applied
Trial Officials
Fernando G Vieira, M.D.
Principal Investigator
ALS Therapy Development Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported